title: Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
authors.affiliation: Institute of Hematology, Università Cattolica Sacro Cuore , Rome , Italy.
authors.forename: Federica
authors.initials: F
authors.lastname: Sorà
authors.forename: Francesco
authors.initials: F
authors.lastname: Autore
authors.forename: Patrizia
authors.initials: P
authors.lastname: Chiusolo
authors.forename: Sara
authors.initials: S
authors.lastname: Marietti
authors.forename: Jolanta
authors.initials: J
authors.lastname: Bayer
authors.forename: Luca
authors.initials: L
authors.lastname: Laurenti
authors.forename: Sabrina
authors.initials: S
authors.lastname: Giammarco
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ausoni
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Simona
authors.initials: S
authors.lastname: Sica
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000627:therapeutic use; D012720:Severity of Illness Index; D013922:Thrombocytosis / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D013927:Thrombosis / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases